ArticleOpen forum infectious diseases2026
Epidemiology and Risk Factors for Infection in Multiple Myeloma Patients Treated With Bispecific Antibodies.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bispecific antibodies (BsAbs) have revolutionized multiple myeloma (MM) treatment but are associated with infectious complications. This study aims to characterize the incidence, microbiological patterns, and risk factors for infection in this population. Methods: We conducted an observational cohort study of adult MM patients treated with BsAbs at a single center between 2020 and 2025. Clinical and microbiological features of different types of infection were analyzed. Risk factors for recurrent events were assessed by Cox regression. Results: Among 92 patients receiving 98 BsAb courses, 352 infectious episodes were identified (incidence rate: 3.20 episodes per BsAbs course-year). Most common syndromes were respiratory (71.3%) and digestive (11.9%), with predominant viral etiology (62.8%). Severe (grade ≥3) infections occurred in 45.9% of courses. Anti-BCMA BsAbs carried a higher infection risk than anti-GPRC5D therapy (aHR: 1.41, 95% CI: 1.02-1.94; Conclusions: BsAb therapy for MM is associated with a high infection burden, predominantly respiratory and gastrointestinal. Risk is driven by cumulative immunosuppression and therapy for ICANS, while IVIg therapy reduces this susceptibility. Infections are uncommon during CRS episodes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.